查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1591807

基因檢測市場：按疾病類型、技術、應用和最終用戶分類 - 全球預測 2025-2030

Hereditary Testing Market by Disease Type (Hereditary Cancer Testing, Hereditary Non-Cancer Testing, Newborn Genetic Screening), Technology (Biochemical, Cytogenetic, Molecular Testing), Application, End-User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 197 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

基因檢測市場2023年估值為51.5億美元，預計2024年將達55.7億美元，複合年成長率為8.17%，預計到2030年將達到89.3億美元。

基因檢測也稱為基因檢測，透過分析DNA來識別基因、染色體和蛋白質的變化，以幫助檢測遺傳性疾病。基因檢測的範圍包括診斷、預測、帶因者檢測、產前篩檢和新生兒篩檢。這項需求是由對早期疾病檢測、個人化醫療和公眾對遺傳疾病認知不斷提高的需求不斷成長所推動的。此測試可應用於腫瘤學、心臟病學和神經學等多個領域，可供醫療保健專業人員、患者和研究人員使用。市場成長主要受到次世代定序、政府資助增加和遺傳病患病率上升等技術進步的影響。個人化醫療在新興市場的擴張存在著商機，而人工智慧用於資料分析和解釋的整合可以提高測試的準確性和速度。抓住這些機會的建議包括投資研發以提高測試準確性和可負擔性，並促進與醫療保健提供者的合作以實現更廣泛的覆蓋範圍。

主要市場統計
基準年[2023] 51.5億美元
預測年份 [2024] 55.7億美元
預測年份 [2030] 89.3億美元
複合年成長率（%） 8.17%

然而，市場面臨挑戰，包括監管障礙、有關基因隱私的道德擔憂以及潛在的保險範圍限制。克服這些限制需要強力的資料隱私措施和公共教育舉措，以減輕道德擔憂。創新成長領域包括非侵入性產前檢測、擴展到藥物基因組學以及開發直接面對消費者的檢測套組。市場充滿活力，競爭激烈，技術進步迅速，需要不斷創新與適應。公司可以透過策略夥伴關係和行銷宣傳活動來重點提高負擔能力和意識。總體而言，利用技術和醫療保健的交叉點對於利用蓬勃發展的基因檢測市場至關重要。

市場動態：揭示快速發展的基因檢測市場的關鍵市場洞察

供需的動態交互作用正在改變基因檢測市場。透過了解這些不斷變化的市場動態，公司可以準備好做出明智的投資決策、完善策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，同時也能幫助企業了解消費行為及其對製造業的影響。

  • 市場促進因素
    • 探索 DNA 變化和變異以找到疾病的潛在根源
    • 增加孕婦篩檢
    • 活性化基因組定序的研發活動
  • 市場限制因素
    • 有限報銷政策
  • 市場機會
    • 聯合產品開發
    • 價值鏈內有吸引力的投資和併購活動
  • 市場挑戰
    • 基因檢測結果不確定

波特五力：駕馭基因檢測市場的策略工具

波特的五力架構是了解基因檢測市場競爭格局的重要工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：了解基因檢測市場的外部影響

外部宏觀環境因素在塑造基因檢測市場的表現動態方面發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並為他們做出積極主動的決策做好準備。

市場佔有率分析 了解基因檢測市場的競爭格局

對基因檢測市場的詳細市場佔有率分析可以對供應商的績效進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV定位矩陣基因檢測市場供應商績效評估

FPNV定位矩陣是評估基因檢測市場供應商的重要工具。此矩陣允許業務組織根據商務策略和產品滿意度評估供應商，從而做出與其目標相符的明智決策。這四個象限使您能夠清晰、準確地分類供應商，以確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析與建議，規劃基因檢測市場的成功之路

基因檢測市場的策略分析對於旨在加強其在全球市場的影響力的公司至關重要。透過考慮關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機並取得長期成功。

本報告對市場進行了全面分析，涵蓋關鍵重點領域：

1. 市場滲透率：對當前市場環境的詳細審查、主要企業的廣泛資料、對其在市場中的影響力和整體影響力的評估。

2. 市場開拓：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監理核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點在於有望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，幫助相關人員做出明智的決策：

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3.塑造市場的主要技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 研究 DNA 的變化和突變，找出潛在疾病的根本原因
      • 增加孕婦篩檢測試
      • 活性化與基因組序列分析的進步相關的研究開發活動
    • 抑制因素
      • 有限退費政策
    • 機會
      • 聯合產品開發
      • 價值鏈內有吸引力的投資和併購活動
    • 任務
      • 基因檢測結果不確定
  • 市場區隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境

第6章 基因檢測市場：依疾病類型

  • 遺傳性癌症檢測
    • 乳癌
    • 子宮頸癌
    • 大腸直腸癌
    • 肺癌
    • 惡性黑色素瘤
    • 卵巢癌
    • 胰臟癌
    • 攝護腺癌
    • 肉瘤
    • 胃癌
    • 子宮癌
  • 遺傳性非癌症檢測
    • 基因檢測
      • 心臟病
      • 罕見疾病
  • 新生兒基因篩檢
  • 無創產前檢測和帶因者篩檢測試
  • 胚胎著床前遺傳診斷與篩檢

第7章 基因檢測市場：依技術分類

  • 生化
  • 細胞遺傳學
  • 分子檢測

第8章 基因檢測市場：依應用分類

  • 癌症診斷
  • 心血管疾病的診斷
  • 遺傳性疾病的診斷

第9章 基因檢測市場：依最終使用者分類

  • 診所
  • 醫院

第10章美洲基因檢測市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第11章亞太基因檢測市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第12章 歐洲、中東和非洲基因檢測市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第13章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
  • 戰略分析和建議

公司名單

  • BGI Genomics Co., Ltd.
  • Biocartis NV
  • CENTOGENE NV
  • CooperSurgical, Inc.
  • CSL Behring
  • Eurofins Scientific SE
  • F. Hoffmann-La Roche Ltd.
  • Invitae Corporation
  • Konica Minolta, Inc.
  • Medgenome
  • Myriad Genetics, Inc.
  • Natera Inc.
  • Quest Diagnostics Incorporated
  • Siemens Healthineers AG
  • SOPHiA Genetics
Product Code: MRR-A339DAEFA85A

The Hereditary Testing Market was valued at USD 5.15 billion in 2023, expected to reach USD 5.57 billion in 2024, and is projected to grow at a CAGR of 8.17%, to USD 8.93 billion by 2030.

Hereditary testing, also known as genetic testing, involves analyzing DNA to identify changes in genes, chromosomes, or proteins, helping detect genetic disorders. The scope of hereditary testing encompasses diagnostic, predictive, and carrier testing, as well as prenatal and newborn screening. Its necessity is driven by the increasing need for early disease detection, personalized medicine, and growing public awareness about genetic disorders. It is applied in various areas, including oncology, cardiology, and neurology, catering to healthcare professionals, patients, and researchers. Market growth is primarily influenced by technological advancements like next-generation sequencing, increased government funding, and a rising prevalence of genetic diseases. Opportunities lie in expanding personalized medicine within emerging markets, and the integration of AI for data analysis and interpretation can enhance testing accuracy and speed. Recommendations to seize these opportunities include investing in R&D to improve test accuracy and affordability, and fostering collaborations with healthcare providers for wider reach.

KEY MARKET STATISTICS
Base Year [2023] USD 5.15 billion
Estimated Year [2024] USD 5.57 billion
Forecast Year [2030] USD 8.93 billion
CAGR (%) 8.17%

However, the market faces challenges such as regulatory hurdles, ethical concerns surrounding genetic privacy, and potential insurance coverage limitations. Overcoming these limitations requires robust data privacy measures and public education initiatives to alleviate ethical concerns. Innovative areas for growth include non-invasive prenatal testing, expansion into pharmacogenomics, and the development of direct-to-consumer testing kits. The market is highly dynamic, characterized by increased competition and rapid technological advancements, necessitating continuous innovation and adaptation. Companies might focus on increasing affordability and awareness through strategic partnerships and marketing campaigns. Overall, leveraging the intersection of technology and healthcare will be crucial for capitalizing on the booming hereditary testing market.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Hereditary Testing Market

The Hereditary Testing Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Exploration for changes or variants, in DNA to find root cause of potential disease
    • Increased screening by pregnant women
    • Rising R&D activities on advance Genome sequencing
  • Market Restraints
    • Limited reimbursement policies
  • Market Opportunities
    • Collaborative product development
    • Attractive investment and amalgamation activity within value chain
  • Market Challenges
    • Uncertain outcomes of the hereditary testing

Porter's Five Forces: A Strategic Tool for Navigating the Hereditary Testing Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Hereditary Testing Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Hereditary Testing Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Hereditary Testing Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Hereditary Testing Market

A detailed market share analysis in the Hereditary Testing Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Hereditary Testing Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Hereditary Testing Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Hereditary Testing Market

A strategic analysis of the Hereditary Testing Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Hereditary Testing Market, highlighting leading vendors and their innovative profiles. These include BGI Genomics Co., Ltd., Biocartis NV, CENTOGENE N.V., CooperSurgical, Inc., CSL Behring, Eurofins Scientific SE, F. Hoffmann-La Roche Ltd., Invitae Corporation, Konica Minolta, Inc., Medgenome, Myriad Genetics, Inc., Natera Inc., Quest Diagnostics Incorporated, Siemens Healthineers AG, and SOPHiA Genetics.

Market Segmentation & Coverage

This research report categorizes the Hereditary Testing Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Disease Type, market is studied across Hereditary Cancer Testing, Hereditary Non-Cancer Testing, Newborn Genetic Screening, Non-Invasive Prenatal Testing & Carrier Screening Tests, and Preimplantation Genetic Diagnosis & Screening. The Hereditary Cancer Testing is further studied across Breast Cancer, Cervical Cancer, Colorectal Cancer, Lung Cancer, Melanoma, Ovarian Cancer, Pancreatic Cancer, Prostate Cancer, Sarcoma, Stomach or Gastric Cancer, and Uterine Cancer. The Hereditary Non-Cancer Testing is further studied across Genetic Tests. The Genetic Tests is further studied across Cardiac Diseases and Rare Diseases.
  • Based on Technology, market is studied across Biochemical, Cytogenetic, and Molecular Testing.
  • Based on Application, market is studied across Cancer Diagnosis, Cardiovascular Disease Diagnosis, and Genetic Disease Diagnosis.
  • Based on End-User, market is studied across Clinics and Hospitals.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Exploration for changes or variants, in DNA to find root cause of potential disease
      • 5.1.1.2. Increased screening by pregnant women
      • 5.1.1.3. Rising R&D activities on advance Genome sequencing
    • 5.1.2. Restraints
      • 5.1.2.1. Limited reimbursement policies
    • 5.1.3. Opportunities
      • 5.1.3.1. Collaborative product development
      • 5.1.3.2. Attractive investment and amalgamation activity within value chain
    • 5.1.4. Challenges
      • 5.1.4.1. Uncertain outcomes of the hereditary testing
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Hereditary Testing Market, by Disease Type

  • 6.1. Introduction
  • 6.2. Hereditary Cancer Testing
    • 6.2.1. Breast Cancer
    • 6.2.2. Cervical Cancer
    • 6.2.3. Colorectal Cancer
    • 6.2.4. Lung Cancer
    • 6.2.5. Melanoma
    • 6.2.6. Ovarian Cancer
    • 6.2.7. Pancreatic Cancer
    • 6.2.8. Prostate Cancer
    • 6.2.9. Sarcoma
    • 6.2.10. Stomach or Gastric Cancer
    • 6.2.11. Uterine Cancer
  • 6.3. Hereditary Non-Cancer Testing
    • 6.3.1. Genetic Tests
      • 6.3.1.1. Cardiac Diseases
      • 6.3.1.2. Rare Diseases
  • 6.4. Newborn Genetic Screening
  • 6.5. Non-Invasive Prenatal Testing & Carrier Screening Tests
  • 6.6. Preimplantation Genetic Diagnosis & Screening

7. Hereditary Testing Market, by Technology

  • 7.1. Introduction
  • 7.2. Biochemical
  • 7.3. Cytogenetic
  • 7.4. Molecular Testing

8. Hereditary Testing Market, by Application

  • 8.1. Introduction
  • 8.2. Cancer Diagnosis
  • 8.3. Cardiovascular Disease Diagnosis
  • 8.4. Genetic Disease Diagnosis

9. Hereditary Testing Market, by End-User

  • 9.1. Introduction
  • 9.2. Clinics
  • 9.3. Hospitals

10. Americas Hereditary Testing Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Hereditary Testing Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Hereditary Testing Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2023
  • 13.2. FPNV Positioning Matrix, 2023
  • 13.3. Competitive Scenario Analysis
  • 13.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. BGI Genomics Co., Ltd.
  • 2. Biocartis NV
  • 3. CENTOGENE N.V.
  • 4. CooperSurgical, Inc.
  • 5. CSL Behring
  • 6. Eurofins Scientific SE
  • 7. F. Hoffmann-La Roche Ltd.
  • 8. Invitae Corporation
  • 9. Konica Minolta, Inc.
  • 10. Medgenome
  • 11. Myriad Genetics, Inc.
  • 12. Natera Inc.
  • 13. Quest Diagnostics Incorporated
  • 14. Siemens Healthineers AG
  • 15. SOPHiA Genetics

LIST OF FIGURES

  • FIGURE 1. HEREDITARY TESTING MARKET RESEARCH PROCESS
  • FIGURE 2. HEREDITARY TESTING MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL HEREDITARY TESTING MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL HEREDITARY TESTING MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL HEREDITARY TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL HEREDITARY TESTING MARKET SIZE, BY DISEASE TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL HEREDITARY TESTING MARKET SIZE, BY DISEASE TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL HEREDITARY TESTING MARKET SIZE, BY TECHNOLOGY, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL HEREDITARY TESTING MARKET SIZE, BY TECHNOLOGY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL HEREDITARY TESTING MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL HEREDITARY TESTING MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL HEREDITARY TESTING MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL HEREDITARY TESTING MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. AMERICAS HEREDITARY TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. AMERICAS HEREDITARY TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. UNITED STATES HEREDITARY TESTING MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 17. UNITED STATES HEREDITARY TESTING MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC HEREDITARY TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. ASIA-PACIFIC HEREDITARY TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA HEREDITARY TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. EUROPE, MIDDLE EAST & AFRICA HEREDITARY TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. HEREDITARY TESTING MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 23. HEREDITARY TESTING MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. HEREDITARY TESTING MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL HEREDITARY TESTING MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL HEREDITARY TESTING MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL HEREDITARY TESTING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. HEREDITARY TESTING MARKET DYNAMICS
  • TABLE 7. GLOBAL HEREDITARY TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL HEREDITARY TESTING MARKET SIZE, BY HEREDITARY CANCER TESTING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL HEREDITARY TESTING MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL HEREDITARY TESTING MARKET SIZE, BY CERVICAL CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL HEREDITARY TESTING MARKET SIZE, BY COLORECTAL CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL HEREDITARY TESTING MARKET SIZE, BY LUNG CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL HEREDITARY TESTING MARKET SIZE, BY MELANOMA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL HEREDITARY TESTING MARKET SIZE, BY OVARIAN CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL HEREDITARY TESTING MARKET SIZE, BY PANCREATIC CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL HEREDITARY TESTING MARKET SIZE, BY PROSTATE CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL HEREDITARY TESTING MARKET SIZE, BY SARCOMA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL HEREDITARY TESTING MARKET SIZE, BY STOMACH OR GASTRIC CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL HEREDITARY TESTING MARKET SIZE, BY UTERINE CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL HEREDITARY TESTING MARKET SIZE, BY HEREDITARY CANCER TESTING, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL HEREDITARY TESTING MARKET SIZE, BY HEREDITARY NON-CANCER TESTING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL HEREDITARY TESTING MARKET SIZE, BY GENETIC TESTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL HEREDITARY TESTING MARKET SIZE, BY CARDIAC DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL HEREDITARY TESTING MARKET SIZE, BY RARE DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL HEREDITARY TESTING MARKET SIZE, BY GENETIC TESTS, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL HEREDITARY TESTING MARKET SIZE, BY HEREDITARY NON-CANCER TESTING, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL HEREDITARY TESTING MARKET SIZE, BY NEWBORN GENETIC SCREENING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL HEREDITARY TESTING MARKET SIZE, BY NON-INVASIVE PRENATAL TESTING & CARRIER SCREENING TESTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL HEREDITARY TESTING MARKET SIZE, BY PREIMPLANTATION GENETIC DIAGNOSIS & SCREENING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 30. GLOBAL HEREDITARY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 31. GLOBAL HEREDITARY TESTING MARKET SIZE, BY BIOCHEMICAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 32. GLOBAL HEREDITARY TESTING MARKET SIZE, BY CYTOGENETIC, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 33. GLOBAL HEREDITARY TESTING MARKET SIZE, BY MOLECULAR TESTING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 34. GLOBAL HEREDITARY TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 35. GLOBAL HEREDITARY TESTING MARKET SIZE, BY CANCER DIAGNOSIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 36. GLOBAL HEREDITARY TESTING MARKET SIZE, BY CARDIOVASCULAR DISEASE DIAGNOSIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 37. GLOBAL HEREDITARY TESTING MARKET SIZE, BY GENETIC DISEASE DIAGNOSIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 38. GLOBAL HEREDITARY TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 39. GLOBAL HEREDITARY TESTING MARKET SIZE, BY CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 40. GLOBAL HEREDITARY TESTING MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 41. AMERICAS HEREDITARY TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 42. AMERICAS HEREDITARY TESTING MARKET SIZE, BY HEREDITARY CANCER TESTING, 2018-2030 (USD MILLION)
  • TABLE 43. AMERICAS HEREDITARY TESTING MARKET SIZE, BY HEREDITARY NON-CANCER TESTING, 2018-2030 (USD MILLION)
  • TABLE 44. AMERICAS HEREDITARY TESTING MARKET SIZE, BY GENETIC TESTS, 2018-2030 (USD MILLION)
  • TABLE 45. AMERICAS HEREDITARY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 46. AMERICAS HEREDITARY TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 47. AMERICAS HEREDITARY TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 48. AMERICAS HEREDITARY TESTING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 49. ARGENTINA HEREDITARY TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 50. ARGENTINA HEREDITARY TESTING MARKET SIZE, BY HEREDITARY CANCER TESTING, 2018-2030 (USD MILLION)
  • TABLE 51. ARGENTINA HEREDITARY TESTING MARKET SIZE, BY HEREDITARY NON-CANCER TESTING, 2018-2030 (USD MILLION)
  • TABLE 52. ARGENTINA HEREDITARY TESTING MARKET SIZE, BY GENETIC TESTS, 2018-2030 (USD MILLION)
  • TABLE 53. ARGENTINA HEREDITARY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 54. ARGENTINA HEREDITARY TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 55. ARGENTINA HEREDITARY TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 56. BRAZIL HEREDITARY TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 57. BRAZIL HEREDITARY TESTING MARKET SIZE, BY HEREDITARY CANCER TESTING, 2018-2030 (USD MILLION)
  • TABLE 58. BRAZIL HEREDITARY TESTING MARKET SIZE, BY HEREDITARY NON-CANCER TESTING, 2018-2030 (USD MILLION)
  • TABLE 59. BRAZIL HEREDITARY TESTING MARKET SIZE, BY GENETIC TESTS, 2018-2030 (USD MILLION)
  • TABLE 60. BRAZIL HEREDITARY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 61. BRAZIL HEREDITARY TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 62. BRAZIL HEREDITARY TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 63. CANADA HEREDITARY TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 64. CANADA HEREDITARY TESTING MARKET SIZE, BY HEREDITARY CANCER TESTING, 2018-2030 (USD MILLION)
  • TABLE 65. CANADA HEREDITARY TESTING MARKET SIZE, BY HEREDITARY NON-CANCER TESTING, 2018-2030 (USD MILLION)
  • TABLE 66. CANADA HEREDITARY TESTING MARKET SIZE, BY GENETIC TESTS, 2018-2030 (USD MILLION)
  • TABLE 67. CANADA HEREDITARY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 68. CANADA HEREDITARY TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 69. CANADA HEREDITARY TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 70. MEXICO HEREDITARY TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 71. MEXICO HEREDITARY TESTING MARKET SIZE, BY HEREDITARY CANCER TESTING, 2018-2030 (USD MILLION)
  • TABLE 72. MEXICO HEREDITARY TESTING MARKET SIZE, BY HEREDITARY NON-CANCER TESTING, 2018-2030 (USD MILLION)
  • TABLE 73. MEXICO HEREDITARY TESTING MARKET SIZE, BY GENETIC TESTS, 2018-2030 (USD MILLION)
  • TABLE 74. MEXICO HEREDITARY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 75. MEXICO HEREDITARY TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 76. MEXICO HEREDITARY TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 77. UNITED STATES HEREDITARY TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 78. UNITED STATES HEREDITARY TESTING MARKET SIZE, BY HEREDITARY CANCER TESTING, 2018-2030 (USD MILLION)
  • TABLE 79. UNITED STATES HEREDITARY TESTING MARKET SIZE, BY HEREDITARY NON-CANCER TESTING, 2018-2030 (USD MILLION)
  • TABLE 80. UNITED STATES HEREDITARY TESTING MARKET SIZE, BY GENETIC TESTS, 2018-2030 (USD MILLION)
  • TABLE 81. UNITED STATES HEREDITARY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 82. UNITED STATES HEREDITARY TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 83. UNITED STATES HEREDITARY TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 84. UNITED STATES HEREDITARY TESTING MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 85. ASIA-PACIFIC HEREDITARY TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 86. ASIA-PACIFIC HEREDITARY TESTING MARKET SIZE, BY HEREDITARY CANCER TESTING, 2018-2030 (USD MILLION)
  • TABLE 87. ASIA-PACIFIC HEREDITARY TESTING MARKET SIZE, BY HEREDITARY NON-CANCER TESTING, 2018-2030 (USD MILLION)
  • TABLE 88. ASIA-PACIFIC HEREDITARY TESTING MARKET SIZE, BY GENETIC TESTS, 2018-2030 (USD MILLION)
  • TABLE 89. ASIA-PACIFIC HEREDITARY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 90. ASIA-PACIFIC HEREDITARY TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 91. ASIA-PACIFIC HEREDITARY TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 92. ASIA-PACIFIC HEREDITARY TESTING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 93. AUSTRALIA HEREDITARY TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 94. AUSTRALIA HEREDITARY TESTING MARKET SIZE, BY HEREDITARY CANCER TESTING, 2018-2030 (USD MILLION)
  • TABLE 95. AUSTRALIA HEREDITARY TESTING MARKET SIZE, BY HEREDITARY NON-CANCER TESTING, 2018-2030 (USD MILLION)
  • TABLE 96. AUSTRALIA HEREDITARY TESTING MARKET SIZE, BY GENETIC TESTS, 2018-2030 (USD MILLION)
  • TABLE 97. AUSTRALIA HEREDITARY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 98. AUSTRALIA HEREDITARY TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 99. AUSTRALIA HEREDITARY TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 100. CHINA HEREDITARY TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 101. CHINA HEREDITARY TESTING MARKET SIZE, BY HEREDITARY CANCER TESTING, 2018-2030 (USD MILLION)
  • TABLE 102. CHINA HEREDITARY TESTING MARKET SIZE, BY HEREDITARY NON-CANCER TESTING, 2018-2030 (USD MILLION)
  • TABLE 103. CHINA HEREDITARY TESTING MARKET SIZE, BY GENETIC TESTS, 2018-2030 (USD MILLION)
  • TABLE 104. CHINA HEREDITARY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 105. CHINA HEREDITARY TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 106. CHINA HEREDITARY TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 107. INDIA HEREDITARY TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 108. INDIA HEREDITARY TESTING MARKET SIZE, BY HEREDITARY CANCER TESTING, 2018-2030 (USD MILLION)
  • TABLE 109. INDIA HEREDITARY TESTING MARKET SIZE, BY HEREDITARY NON-CANCER TESTING, 2018-2030 (USD MILLION)
  • TABLE 110. INDIA HEREDITARY TESTING MARKET SIZE, BY GENETIC TESTS, 2018-2030 (USD MILLION)
  • TABLE 111. INDIA HEREDITARY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 112. INDIA HEREDITARY TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 113. INDIA HEREDITARY TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 114. INDONESIA HEREDITARY TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 115. INDONESIA HEREDITARY TESTING MARKET SIZE, BY HEREDITARY CANCER TESTING, 2018-2030 (USD MILLION)
  • TABLE 116. INDONESIA HEREDITARY TESTING MARKET SIZE, BY HEREDITARY NON-CANCER TESTING, 2018-2030 (USD MILLION)
  • TABLE 117. INDONESIA HEREDITARY TESTING MARKET SIZE, BY GENETIC TESTS, 2018-2030 (USD MILLION)
  • TABLE 118. INDONESIA HEREDITARY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 119. INDONESIA HEREDITARY TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 120. INDONESIA HEREDITARY TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 121. JAPAN HEREDITARY TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 122. JAPAN HEREDITARY TESTING MARKET SIZE, BY HEREDITARY CANCER TESTING, 2018-2030 (USD MILLION)
  • TABLE 123. JAPAN HEREDITARY TESTING MARKET SIZE, BY HEREDITARY NON-CANCER TESTING, 2018-2030 (USD MILLION)
  • TABLE 124. JAPAN HEREDITARY TESTING MARKET SIZE, BY GENETIC TESTS, 2018-2030 (USD MILLION)
  • TABLE 125. JAPAN HEREDITARY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 126. JAPAN HEREDITARY TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 127. JAPAN HEREDITARY TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 128. MALAYSIA HEREDITARY TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 129. MALAYSIA HEREDITARY TESTING MARKET SIZE, BY HEREDITARY CANCER TESTING, 2018-2030 (USD MILLION)
  • TABLE 130. MALAYSIA HEREDITARY TESTING MARKET SIZE, BY HEREDITARY NON-CANCER TESTING, 2018-2030 (USD MILLION)
  • TABLE 131. MALAYSIA HEREDITARY TESTING MARKET SIZE, BY GENETIC TESTS, 2018-2030 (USD MILLION)
  • TABLE 132. MALAYSIA HEREDITARY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 133. MALAYSIA HEREDITARY TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 134. MALAYSIA HEREDITARY TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 135. PHILIPPINES HEREDITARY TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 136. PHILIPPINES HEREDITARY TESTING MARKET SIZE, BY HEREDITARY CANCER TESTING, 2018-2030 (USD MILLION)
  • TABLE 137. PHILIPPINES HEREDITARY TESTING MARKET SIZE, BY HEREDITARY NON-CANCER TESTING, 2018-2030 (USD MILLION)
  • TABLE 138. PHILIPPINES HEREDITARY TESTING MARKET SIZE, BY GENETIC TESTS, 2018-2030 (USD MILLION)
  • TABLE 139. PHILIPPINES HEREDITARY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 140. PHILIPPINES HEREDITARY TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 141. PHILIPPINES HEREDITARY TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 142. SINGAPORE HEREDITARY TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 143. SINGAPORE HEREDITARY TESTING MARKET SIZE, BY HEREDITARY CANCER TESTING, 2018-2030 (USD MILLION)
  • TABLE 144. SINGAPORE HEREDITARY TESTING MARKET SIZE, BY HEREDITARY NON-CANCER TESTING, 2018-2030 (USD MILLION)
  • TABLE 145. SINGAPORE HEREDITARY TESTING MARKET SIZE, BY GENETIC TESTS, 2018-2030 (USD MILLION)
  • TABLE 146. SINGAPORE HEREDITARY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 147. SINGAPORE HEREDITARY TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 148. SINGAPORE HEREDITARY TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 149. SOUTH KOREA HEREDITARY TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 150. SOUTH KOREA HEREDITARY TESTING MARKET SIZE, BY HEREDITARY CANCER TESTING, 2018-2030 (USD MILLION)
  • TABLE 151. SOUTH KOREA HEREDITARY TESTING MARKET SIZE, BY HEREDITARY NON-CANCER TESTING, 2018-2030 (USD MILLION)
  • TABLE 152. SOUTH KOREA HEREDITARY TESTING MARKET SIZE, BY GENETIC TESTS, 2018-2030 (USD MILLION)
  • TABLE 153. SOUTH KOREA HEREDITARY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 154. SOUTH KOREA HEREDITARY TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 155. SOUTH KOREA HEREDITARY TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 156. TAIWAN HEREDITARY TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 157. TAIWAN HEREDITARY TESTING MARKET SIZE, BY HEREDITARY CANCER TESTING, 2018-2030 (USD MILLION)
  • TABLE 158. TAIWAN HEREDITARY TESTING MARKET SIZE, BY HEREDITARY NON-CANCER TESTING, 2018-2030 (USD MILLION)
  • TABLE 159. TAIWAN HEREDITARY TESTING MARKET SIZE, BY GENETIC TESTS, 2018-2030 (USD MILLION)
  • TABLE 160. TAIWAN HEREDITARY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 161. TAIWAN HEREDITARY TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 162. TAIWAN HEREDITARY TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 163. THAILAND HEREDITARY TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 164. THAILAND HEREDITARY TESTING MARKET SIZE, BY HEREDITARY CANCER TESTING, 2018-2030 (USD MILLION)
  • TABLE 165. THAILAND HEREDITARY TESTING MARKET SIZE, BY HEREDITARY NON-CANCER TESTING, 2018-2030 (USD MILLION)
  • TABLE 166. THAILAND HEREDITARY TESTING MARKET SIZE, BY GENETIC TESTS, 2018-2030 (USD MILLION)
  • TABLE 167. THAILAND HEREDITARY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 168. THAILAND HEREDITARY TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 169. THAILAND HEREDITARY TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 170. VIETNAM HEREDITARY TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 171. VIETNAM HEREDITARY TESTING MARKET SIZE, BY HEREDITARY CANCER TESTING, 2018-2030 (USD MILLION)
  • TABLE 172. VIETNAM HEREDITARY TESTING MARKET SIZE, BY HEREDITARY NON-CANCER TESTING, 2018-2030 (USD MILLION)
  • TABLE 173. VIETNAM HEREDITARY TESTING MARKET SIZE, BY GENETIC TESTS, 2018-2030 (USD MILLION)
  • TABLE 174. VIETNAM HEREDITARY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 175. VIETNAM HEREDITARY TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 176. VIETNAM HEREDITARY TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 177. EUROPE, MIDDLE EAST & AFRICA HEREDITARY TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 178. EUROPE, MIDDLE EAST & AFRICA HEREDITARY TESTING MARKET SIZE, BY HEREDITARY CANCER TESTING, 2018-2030 (USD MILLION)
  • TABLE 179. EUROPE, MIDDLE EAST & AFRICA HEREDITARY TESTING MARKET SIZE, BY HEREDITARY NON-CANCER TESTING, 2018-2030 (USD MILLION)
  • TABLE 180. EUROPE, MIDDLE EAST & AFRICA HEREDITARY TESTING MARKET SIZE, BY GENETIC TESTS, 2018-2030 (USD MILLION)
  • TABLE 181. EUROPE, MIDDLE EAST & AFRICA HEREDITARY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 182. EUROPE, MIDDLE EAST & AFRICA HEREDITARY TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 183. EUROPE, MIDDLE EAST & AFRICA HEREDITARY TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 184. EUROPE, MIDDLE EAST & AFRICA HEREDITARY TESTING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 185. DENMARK HEREDITARY TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 186. DENMARK HEREDITARY TESTING MARKET SIZE, BY HEREDITARY CANCER TESTING, 2018-2030 (USD MILLION)
  • TABLE 187. DENMARK HEREDITARY TESTING MARKET SIZE, BY HEREDITARY NON-CANCER TESTING, 2018-2030 (USD MILLION)
  • TABLE 188. DENMARK HEREDITARY TESTING MARKET SIZE, BY GENETIC TESTS, 2018-2030 (USD MILLION)
  • TABLE 189. DENMARK HEREDITARY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 190. DENMARK HEREDITARY TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 191. DENMARK HEREDITARY TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 192. EGYPT HEREDITARY TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 193. EGYPT HEREDITARY TESTING MARKET SIZE, BY HEREDITARY CANCER TESTING, 2018-2030 (USD MILLION)
  • TABLE 194. EGYPT HEREDITARY TESTING MARKET SIZE, BY HEREDITARY NON-CANCER TESTING, 2018-2030 (USD MILLION)
  • TABLE 195. EGYPT HEREDITARY TESTING MARKET SIZE, BY GENETIC TESTS, 2018-2030 (USD MILLION)
  • TABLE 196. EGYPT HEREDITARY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 197. EGYPT HEREDITARY TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 198. EGYPT HEREDITARY TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 199. FINLAND HEREDITARY TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 200. FINLAND HEREDITARY TESTING MARKET SIZE, BY HEREDITARY CANCER TESTING, 2018-2030 (USD MILLION)
  • TABLE 201. FINLAND HEREDITARY TESTING MARKET SIZE, BY HEREDITARY NON-CANCER TESTING, 2018-2030 (USD MILLION)
  • TABLE 202. FINLAND HEREDITARY TESTING MARKET SIZE, BY GENETIC TESTS, 2018-2030 (USD MILLION)
  • TABLE 203. FINLAND HEREDITARY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 204. FINLAND HEREDITARY TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 205. FINLAND HEREDITARY TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 206. FRANCE HEREDITARY TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 207. FRANCE HEREDITARY TESTING MARKET SIZE, BY HEREDITARY CANCER TESTING, 2018-2030 (USD MILLION)
  • TABLE 208. FRANCE HEREDITARY TESTING MARKET SIZE, BY HEREDITARY NON-CANCER TESTING, 2018-2030 (USD MILLION)
  • TABLE 209. FRANCE HEREDITARY TESTING MARKET SIZE, BY GENETIC TESTS, 2018-2030 (USD MILLION)
  • TABLE 210. FRANCE HEREDITARY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 211. FRANCE HEREDITARY TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 212. FRANCE HEREDITARY TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 213. GERMANY HEREDITARY TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 214. GERMANY HEREDITARY TESTING MARKET SIZE, BY HEREDITARY CANCER TESTING, 2018-2030 (USD MILLION)
  • TABLE 215. GERMANY HEREDITARY TESTING MARKET SIZE, BY HEREDITARY NON-CANCER TESTING, 2018-2030 (USD MILLION)
  • TABLE 216. GERMANY HEREDITARY TESTING MARKET SIZE, BY GENETIC TESTS, 2018-2030 (USD MILLION)
  • TABLE 217. GERMANY HEREDITARY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 218. GERMANY HEREDITARY TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 219. GERMANY HEREDITARY TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 220. ISRAEL HEREDITARY TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 221. ISRAEL HEREDITARY TESTING MARKET SIZE, BY HEREDITARY CANCER TESTING, 2018-2030 (USD MILLION)
  • TABLE 222. ISRAEL HEREDITARY TESTING MARKET SIZE, BY HEREDITARY NON-CANCER TESTING, 2018-2030 (USD MILLION)
  • TABLE 223. ISRAEL HEREDITARY TESTING MARKET SIZE, BY GENETIC TESTS, 2018-2030 (USD MILLION)
  • TABLE 224. ISRAEL HEREDITARY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 225. ISRAEL HEREDITARY TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 226. ISRAEL HEREDITARY TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 227. ITALY HEREDITARY TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 228. ITALY HEREDITARY TESTING MARKET SIZE, BY HEREDITARY CANCER TESTING, 2018-2030 (USD MILLION)
  • TABLE 229. ITALY HEREDITARY TESTING MARKET SIZE, BY HEREDITARY NON-CANCER TESTING, 2018-2030 (USD MILLION)
  • TABLE 230. ITALY HEREDITARY TESTING MARKET SIZE, BY GENETIC TESTS, 2018-2030 (USD MILLION)
  • TABLE 231. ITALY HEREDITARY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 232. ITALY HEREDITARY TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 233. ITALY HEREDITARY TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 234. NETHERLANDS HEREDITARY TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 235. NETHERLANDS HEREDITARY TESTING MARKET SIZE, BY HEREDITARY CANCER TESTING, 2018-2030 (USD MILLION)
  • TABLE 236. NETHERLANDS HEREDITARY TESTING MARKET SIZE, BY HEREDITARY NON-CANCER TESTING, 2018-2030 (USD MILLION)
  • TABLE 237. NETHERLANDS HEREDITARY TESTING MARKET SIZE, BY GENETIC TESTS, 2018-2030 (USD MILLION)
  • TABLE 238. NETHERLANDS HEREDITARY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 239. NETHERLANDS HEREDITARY TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 240. NETHERLANDS HEREDITARY TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 241. NIGERIA HEREDITARY TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 242. NIGERIA HEREDITARY TESTING MARKET SIZE, BY HEREDITARY CANCER TESTING, 2018-2030 (USD MILLION)
  • TABLE 243. NIGERIA HEREDITARY TESTING MARKET SIZE, BY HEREDITARY NON-CANCER TESTING, 2018-2030 (USD MILLION)
  • TABLE 244. NIGERIA HEREDITARY TESTING MARKET SIZE, BY GENETIC TESTS, 2018-2030 (USD MILLION)
  • TABLE 245. NIGERIA HEREDITARY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 246. NIGERIA HEREDITARY TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 247. NIGERIA HEREDITARY TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 248. NORWAY HEREDITARY TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 249. NORWAY HEREDITARY TESTING MARKET SIZE, BY HEREDITARY CANCER TESTING, 2018-2030 (USD MILLION)
  • TABLE 250. NORWAY HEREDITARY TESTING MARKET SIZE, BY HEREDITARY NON-CANCER TESTING, 2018-2030 (USD MILLION)
  • TABLE 251. NORWAY HEREDITARY TESTING MARKET SIZE, BY GENETIC TESTS, 2018-2030 (USD MILLION)
  • TABLE 252. NORWAY HEREDITARY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 253. NORWAY HEREDITARY TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 254. NORWAY HEREDITARY TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 255. POLAND HEREDITARY TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 256. POLAND HEREDITARY TESTING MARKET SIZE, BY HEREDITARY CANCER TESTING, 2018-2030 (USD MILLION)
  • TABLE 257. POLAND HEREDITARY TESTING MARKET SIZE, BY HEREDITARY NON-CANCER TESTING, 2018-2030 (USD MILLION)
  • TABLE 258. POLAND HEREDITARY TESTING MARKET SIZE, BY GENETIC TESTS, 2018-2030 (USD MILLION)
  • TABLE 259. POLAND HEREDITARY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 260. POLAND HEREDITARY TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 261. POLAND HEREDITARY TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 262. QATAR HEREDITARY TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 263. QATAR HEREDITARY TESTING MARKET SIZE, BY HEREDITARY CANCER TESTING, 2018-2030 (USD MILLION)
  • TABLE 264. QATAR HEREDITARY TESTING MARKET SIZE, BY HEREDITARY NON-CANCER TESTING, 2018-2030 (USD MILLION)
  • TABLE 265. QATAR HEREDITARY TESTING MARKET SIZE, BY GENETIC TESTS, 2018-2030 (USD MILLION)
  • TABLE 266. QATAR HEREDITARY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 267. QATAR HEREDITARY TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 268. QATAR HEREDITARY TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 269. RUSSIA HEREDITARY TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 270. RUSSIA HEREDITARY TESTING MARKET SIZE, BY HEREDITARY CANCER TESTING, 2018-2030 (USD MILLION)
  • TABLE 271. RUSSIA HEREDITARY TESTING MARKET SIZE, BY HEREDITARY NON-CANCER TESTING, 2018-2030 (USD MILLION)
  • TABLE 272. RUSSIA HEREDITARY TESTING MARKET SIZE, BY GENETIC TESTS, 2018-2030 (USD MILLION)
  • TABLE 273. RUSSIA HEREDITARY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 274. RUSSIA HEREDITARY TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 275. RUSSIA HEREDITARY TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 276. SAUDI ARABIA HEREDITARY TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 277. SAUDI ARABIA HEREDITARY TESTING MARKET SIZE, BY HEREDITARY CANCER TESTING, 2018-2030 (USD MILLION)
  • TABLE 278. SAUDI ARABIA HEREDITARY TESTING MARKET SIZE, BY HEREDITARY NON-CANCER TESTING, 2018-2030 (USD MILLION)
  • TABLE 279. SAUDI ARABIA HEREDITARY TESTING MARKET SIZE, BY GENETIC TESTS, 2018-2030 (USD MILLION)
  • TABLE 280. SAUDI ARABIA HEREDITARY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 281. SAUDI ARABIA HEREDITARY TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 282. SAUDI ARABIA HEREDITARY TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 283. SOUTH AFRICA HEREDITARY TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 284. SOUTH AFRICA HEREDITARY TESTING MARKET SIZE, BY HEREDITARY CANCER TESTING, 2018-2030 (USD MILLION)
  • TABLE 285. SOUTH AFRICA HEREDITARY TESTING MARKET SIZE, BY HEREDITARY NON-CANCER TESTING, 2018-2030 (USD MILLION)
  • TABLE 286. SOUTH AFRICA HEREDITARY TESTING MARKET SIZE, BY GENETIC TESTS, 2018-2030 (USD MILLION)
  • TABLE 287. SOUTH AFRICA HEREDITARY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 288. SOUTH AFRICA HEREDITARY TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 289. SOUTH AFRICA HEREDITARY TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 290. SPAIN HEREDITARY TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 291. SPAIN HEREDITARY TESTING MARKET SIZE, BY HEREDITARY CANCER TESTING, 2018-2030 (USD MILLION)
  • TABLE 292. SPAIN HEREDITARY TESTING MARKET SIZE, BY HEREDITARY NON-CANCER TESTING, 2018-2030 (USD MILLION)
  • TABLE 293. SPAIN HEREDITARY TESTING MARKET SIZE, BY GENETIC TESTS, 2018-2030 (USD MILLION)
  • TABLE 294. SPAIN HEREDITARY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 295. SPAIN HEREDITARY TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 296. SPAIN HEREDITARY TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 297. SWEDEN HEREDITARY TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 298. SWEDEN HEREDITARY TESTING MARKET SIZE, BY HEREDITARY CANCER TESTING, 2018-2030 (USD MILLION)
  • TABLE 299. SWEDEN HEREDITARY TESTING MARKET SIZE, BY HEREDITARY NON-CANCER TESTING, 2018-2030 (USD MILLION)
  • TABLE 300. SWEDEN HEREDITARY TESTING MARKET SIZE, BY GENETIC TESTS, 2018-2030 (USD MILLION)
  • TABLE 301. SWEDEN HEREDITARY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 302. SWEDEN HEREDITARY TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 303. SWEDEN HEREDITARY TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 304. SWITZERLAND HEREDITARY TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 305. SWITZERLAND HEREDITARY TESTING MARKET SIZE, BY HEREDITARY CANCER TESTING, 2018-2030 (USD MILLION)
  • TABLE 306. SWITZERLAND HEREDITARY TESTING MARKET SIZE, BY HEREDITARY NON-CANCER TESTING, 2018-2030 (USD MILLION)
  • TABLE 307. SWITZERLAND HEREDITARY TESTING MARKET SIZE, BY GENETIC TESTS, 2018-2030 (USD MILLION)
  • TABLE 308. SWITZERLAND HEREDITARY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 309. SWITZERLAND HEREDITARY TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 310. SWITZERLAND HEREDITARY TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 311. TURKEY HEREDITARY TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 312. TURKEY HEREDITARY TESTING MARKET SIZE, BY HEREDITARY CANCER TESTING, 2018-2030 (USD MILLION)
  • TABLE 313. TURKEY HEREDITARY TESTING MARKET SIZE, BY HEREDITARY NON-CANCER TESTING, 2018-2030 (USD MILLION)
  • TABLE 314. TURKEY HEREDITARY TESTING MARKET SIZE, BY GENETIC TESTS, 2018-2030 (USD MILLION)
  • TABLE 315. TURKEY HEREDITARY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 316. TURKEY HEREDITARY TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 317. TURKEY HEREDITARY TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 318. UNITED ARAB EMIRATES HEREDITARY TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 319. UNITED ARAB EMIRATES HEREDITARY TESTING MARKET SIZE, BY HEREDITARY CANCER TESTING, 2018-2030 (USD MILLION)
  • TABLE 320. UNITED ARAB EMIRATES HEREDITARY TESTING MARKET SIZE, BY HEREDITARY NON-CANCER TESTING, 2018-2030 (USD MILLION)
  • TABLE 321. UNITED ARAB EMIRATES HEREDITARY TESTING MARKET SIZE, BY GENETIC TESTS, 2018-2030 (USD MILLION)
  • TABLE 322. UNITED ARAB EMIRATES HEREDITARY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 323. UNITED ARAB EMIRATES HEREDITARY TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 324. UNITED ARAB EMIRATES HEREDITARY TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 325. UNITED KINGDOM HEREDITARY TESTING MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 326. UNITED KINGDOM HEREDITARY TESTING MARKET SIZE, BY HEREDITARY CANCER TESTING, 2018-2030 (USD MILLION)
  • TABLE 327. UNITED KINGDOM HEREDITARY TESTING MARKET SIZE, BY HEREDITARY NON-CANCER TESTING, 2018-2030 (USD MILLION)
  • TABLE 328. UNITED KINGDOM HEREDITARY TESTING MARKET SIZE, BY GENETIC TESTS, 2018-2030 (USD MILLION)
  • TABLE 329. UNITED KINGDOM HEREDITARY TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 330. UNITED KINGDOM HEREDITARY TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 331. UNITED KINGDOM HEREDITARY TESTING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 332. HEREDITARY TESTING MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 333. HEREDITARY TESTING MARKET, FPNV POSITIONING MATRIX, 2023